Background: Organ involvement often occurs in early systemic sclerosis and has been related to premature death. Identifying patients at diagnosis at risk of developing early organ involvement would be useful to optimize screening and management strategies. Objective: To develop prediction models for the 5-year development of interstitial lung disease, pulmonary arterial hypertension and death. Methods: A European multicentre inception cohort was created. For modelling, predefined clinical variables with known predictive value at diagnosis were used. Univariate and multivariate regression analysis were done to select baseline predictors and build the prediction models. The models were tested using the area under the receiver operating characteristic curve comparing observed and expected frequencies.
Systemic sclerosis (SSc) is a systemic autoimmune disease characterized by a triad of inflammation, micro-angiopathy and fibrosis, affecting skin and internal organs. This disease has a heterogeneous nature with large differences in severity and extent. Internal organ involvement, including interstitial lung disease (ILD), pulmonary arterial hypertension (PAH), cardiac involvement (CI) and scleroderma renal crisis (SRC), has an unfavourable impact on survival and is the main cause of death in SSc. Five years after diagnosis, 91% of limited cutaneous SSc (lcSSc) patients are still alive, compared with only 84% in the case of diffuse cutaneous SSc (dcSSc) patients. 1 Organ involvement often starts in the early years of the disease. An analysis of the Pittsburgh Scleroderma Databank showed that in up to 70% of patients with dcSSc, organ involvement developed in the first 3 years after disease onset. 2, 3 It is well established that both SRC and ILD occur early in SSc, [4] [5] [6] and in about half of the patients with PAH associated to SSc, PAH is diagnosed within 5 years from disease onset. 7 Treatment in patients with SSc is often initiated only when organ involvement is already clinically apparent. Currently, it is generally accepted that treatment of SSc might be more effective when initiated early in the disease course, before organ involvement is clinically detectable or when it is even absent. In this regard, an increasing number of studies focus on screening and subsequently treating SSc patients with early organ impairment. 8, 9 In clinical practice, it would be useful to know which SSc patients are at risk for the development of organ involvement and consequently premature death. Identified patients at risk might benefit from personalized management, through appropriate screening strategies and prompt treatment, in order to prevent disease progression. Therefore, the development of a risk assessment instrument for patients with early SSc, which can be used at time of diagnosis, would be very useful.
Several studies have developed and/or evaluated prediction models on both organ involvement and survival over the years. [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] However, most of these studies only described either ILD, PAH or survival but not their combination. [10] [11] [12] [13] [16] [17] [18] [19] 23 In addition, some studies evaluated predictive factors in SSc cohorts with short follow-up, 11 others included patients with long-standing SSc 13, 17, 18, 23 or included clinical factors which are detected only after diagnosis. 16, 17, 20 In summary, most studies displayed data that can be applied only to specific subgroups. A single study analyzes risk factors predicting both organ involvement and survival in an unselected cohort of SSc patients. 17 However, this study includes not only baseline clinical data but also follow-up data, making it difficult to apply the results to patients with early SSc, at the time of diagnosis. 15 In order to develop solid prediction models applicable to patients with SSc at time of diagnosis, complete data at that moment in unselected patients is needed. Therefore, the objective of this study is to develop prediction models for the 5-year occurrence of organ involvement (ILD and PAH) and death in an unselected inception cohort of patients with SSc.
Patients and methods

Design
This cohort is a European multicentre inception cohort created from pre-existing databases from participating centres. A total of 735 patients were included from five different rheumatology departments: Nijmegen (Radboud University Medical Centre), Napoli (Università della Campania 'Luigi Vanvitelli' Seconda Università di Napoli), Zurich (University Hospital Zurich), Lund (Lund University) and Cologne (Uniklinik Köln). According to local regulations, the preexisting databases, as well as the present project, were approved by the Ethical Committees in every centre, and patients provided informed consent if needed.
Patients
For the purpose of the present study, patients fulfilling the EULAR/ACR 2013 classification criteria 24 and with follow-up after diagnosis of at least a 5-year duration were selected. The 5-year cutoff represents the early phase in the disease course of SSc 4 and has been previously used in other studies. 7 Clinical variables and data from laboratory tests and imaging were obtained at the time of diagnosis and at least annually during the follow-up. Occurrence of the first non-Raynaud symptom (NR) was appointed as disease onset. For all patients, demographic data, pulmonary function tests, high-resolution computed tomography (HRCT) and echocardiographic data, closest to date of diagnosis, were collected.
For modelling, clinical variables available in our cohort, which had previously demonstrated some predictive value for ILD, PAH or death when evaluated at the time of diagnosis (Table 1) , were used.
Outcomes
The primary outcomes of interest of this study were ILD, PAH, SRC, CI and survival. However, due to the small numbers of SRC and CI, these results were not shown in Table 1 . Interstitial lung disease was defined as bibasilar fibrosis on chest X-ray or fibrosis / ground-glass attenuation on HRCT or lung function test abnormalities with a reduced forced vital capacity of <70% and/or diffusion capacity <80%. Pulmonary function test were subdivided in categories based on their forced vital capacity (FVC) and diffusing capacity of the lung for carbon monoxide (DLCO) results: FVC over or below 70% of predicted and DLCO over 55% or below 70% of predicted.
The diagnosis of PAH was assessed by right heart catheterization, with mean pulmonary arterial pressure of ⩾25 mmHg and normal pulmonary capillary wedge pressure (<15 mmHg) in the absence of ILD. 25 Scleroderma renal crisis was defined as a new onset arterial hypertension (>150/90 mmHg, measured twice over 24 hr) and rapidly progressing renal failure. 26 SSc-related cardiac complications were defined as pericarditis verified by echocardiography, a diastolic dysfunction > grade 1 on echocardiography or an ejection fraction < 50%.
Statistical analysis
Baseline variables were analysed by outcome (ILD, PAH, SRC, CI and death) using one-way analysis of variance (ANOVA), Kruskal-Wallis test or χ 2 test, as appropriate. Missing baseline values were replaced by 20-fold multiple imputation, based on an average of 10%-30% missing values and conditionally on being missing at random. 27 Next, all baseline variables were analysed using univariate binary logistic regression analysis with ILD, PAH and survival as independent variables. Both SRC and CI were not analysed because of the small number of events. Selection for each outcome was based on a deliberately liberal p value of < 0.2, given the direction of the effect is in line with the previous knowledge. For ILD, the variables included in the model were dcSSc, SSc disease duration < 3 years, puffy fingers and antitopoisomerase-I-antibodies. The PAH model consisted of the following variables: age > 65 years, FVC < 70% and DLCO < 55%. Death was predicted best by age > 65 years, male gender, no anti-centromere antibodies, proteinuria, FVC < 70%, PAH at diagnosis.
All selected variables for an outcome were entered in a 'full' multivariate logistic regression model by stepwise backward selection. Age and gender were included by default, except if the p value was > 0.5, to prevent unnecessary bias. The 20 multiple imputed datasets were used for internal validation. A shrinkage factor was applied to all models to improve prediction in new patients. 28 The shrinkage factor was estimated as χ 2 model -df / χ 2 model , referring to the model chi-square ( χ 2 ) and the number of degrees of freedom. 29 Discrimination of the model was tested using the area under the receiver operating characteristic (ROC) curve with 95% confidence intervals. Calibration of the model was analysed using intercept and slope, p value of the Hosmer and Lemeshow test and a probability plot comparing the observed and expected frequencies of ILD, PAH and survival. All analyses are performed using SPSS 22.0.
Results
Patients
Data were available from 735 patients: 460 (62%) from Nijmegen, 116 (16%) from Napoli, 87 (12%) from Zürich, 50 (7%) from Lund and 22 (3%) from Cologne. Patient characteristics are summarized in Table 2 . The number of missing values was <30% in 25/30 variables, 30%-40% in 4 variables and > 80% in 1 variable (anti-RNA polymerase III, which therefore was not imputed). The majority of the patients in this cohort was between 45 and 65 years of age, followed by under 45 years and over 65 years of age; these percentages are comparable with data from literature. One fourth of all patients was male, and also one fourth was classified as dcSSc. The average disease duration from first non-Raynaud SSc symptom to diagnosis was 17 months. Most patients had anti-nuclear antibodies (ANA) (96%). Anti-centromere antibodies (ACA) were found in 29% of the patients and anti-topoisomerase (ATA) antibodies in 34%. In 36% of the patients only a positive ANA was present (no ACA or ATA).
Interestingly, internal organ involvement was already present at SSc diagnosis in 279 (37%) of the patients, most often this concerned ILD (186 out of 279 patients) (lower part of Table 2 ). During the 5-year follow-up period after diagnosis, ILD developed in 128 patients (23%), PAH in 53 patients (8%), SRC in 12 patients (2%), CI in 22 patients (3%) and 88 (12%) patients died. The occurrence of SRC (12 cases) and CI (22 cases) was too low to be included in the subsequent analyses.
Univariate and multivariate logistic regression
Results of the univariate and multivariate logistic regression analysis are shown in Tables 3 and 4 . Twenty-fold multiple imputation was used for patients lost to followup. Baseline values selected for multivariate modelling are shown with their p value in bold. An OR > 1 indicates a higher probability of ILD, PAH or death in the 5-year period after SSc diagnosis. For example, in the final multivariate model for ILD, patients who were classified as dcSSc at diagnosis were almost twice (OR 1.75) as likely to develop ILD in the first 5 years after SSc diagnosis compared with patients not classified as dcSSc at diagnosis.
Discrimination and calibration
The shrinkage factors (ideally: 1, no shrinkage necessary) were 0.83 for the ILD model, 0.80 for the PAH model and 0.93 for the model with death as outcome. Discriminative performance of the three models is shown in the ROC curves in Figure 1(a) . The area under the ROC curve (AUC) of the ILD prediction model was 0.66 (95% CI 0.64-0.67). The PAH model had an AUC of 0.66 (95% CI 0.64-0.68). The model with death as outcome had an AUC of 0.70 (95% CI 0.69-0.72). Figure 1(b) shows a plot of the proportions of the probability of an event (ILD, PAH or death) against the maximal score of the models applied to the individual patients. It shows that the probability of an event increases with the presence or absence of different variables included in the models. As expected, the relations are non-linear. Especially in ILD, the curve does not cover the full range of probabilities while it has a flat slope, indicating lower prognostic performance. Figure 2 shows the agreement of expected and observed probabilities of the three prediction models. The calibration slope (95% CI) were 0.97 (0.61-1.33) in the ILD model, 0.59 (0.29-0.89) in the PAH model and 0.54 (0.40-0.68) in the model with death as outcome, which means a calibration close to 1 for the ILD model and deviating from 1 for the PAH and death model, compared with the baseline model. In Figure 2 , the observed and expected number of events are displayed in deciles. The non-significance of the Hosmer and Lemeshow test in the ILD and PAH model (p = 0.50; p = 0.39) indicates that the numbers of patients predicted to develop ILD or PAH were in agreement with the numbers observed. The Deciles were created based on increasing probability of an event (development of ILD or PAH, or death). For example, in the first decile (lowest probability of ILD), it was predicted that six patients would develop ILD, while seven patients were observed to have ILD. The consequent probability of dcSSc was (6/127) × 100% ≈ 5%. The higher deciles had a higher number of predicted and observed ILD and therefore an increasing probability of developing ILD. Thus, the more factors predictive for either ILD, PAH or death, present in SSc patients, the greater the risk for development of such event. 
Discussion
Risk stratification in SSc patients is an important issue.
Intensifying screening strategies and timely starting treatment to prevent irreversible organ damage in high-risk subgroups may improve prognosis. The objective of our study was to develop prediction models for the 5-year occurrence of organ involvement and death in an unselected cohort of early SSc patients. In order to develop these models, we used clinical variables with known predictive value which were also generally available in all patients at the time of initial SSc diagnosis. The results of the univariate analysis in this study show that several baseline variables have predictive value for organ involvement and death. Multivariate logistic regression modelling resulted in three final prediction models, including age, gender, disease subtype, disease duration, puffy fingers, auto-antibodies, proteinuria, pulmonary function test results and presence of PAH at SSc diagnosis.
It is worth noting that an age > 65 years at diagnosis was found to have a protective value for the development of ILD, while it was predictive of the development of PAH and death. This result can be easily attributed to likely comorbidities as far as death is concerned; it might intriguingly mean that patients developing SSc late in life course are at a lower risk of ILD.
Performance of all three models was moderate. Sensitivity was set at a minimum of 80%, resulting in a rather low specificity between 30% and 42%. Calibration of the ILD and PAH model showed to be tolerable, according to the non-significant Hosmer and Lemeshow test. However, in the model for death, the observed and expected probabilities did not agree, as reflected by the significant Hosmer and Lemeshow test. Despite the moderate performance of the models, the results show that prediction of organ involvement and death based on different clinical, laboratory and function test results is possible.
In everyday clinical practice, it is of the utmost importance to recognize development of organ involvement in an early stage of SSc. The available treatment options might be more effective if applied timely, before organ involvement becomes clinically apparent and damage is already irreversible. Therefore, prediction of organ involvement and death at diagnosis may be critical for intensifying both screening strategies and treatment. This study states some predictive value in several different clinical characteristics. However, our results do not allow us to give a perfect risk stratification for early SSc patients. Nevertheless, the present study could serve as a starting point to improve risk stratification in early SSc by using large sets of patients with extended follow-up, and inclusion of other variables, such as modified Rodnan Skin Score (mRSS) trend, anti-RNA polymerase-III and other auto-antibodies in order to design solid clinical prediction models.
The main strength of our study is the inclusion of an unselected cohort of early SSc patients with extended follow-up from the time of diagnosis, using only possible predictors easily available at baseline. In previous studies, numerous factors have been found to be more or less predictive for organ involvement and death. However, no clinical (set of) biomarker(s) able to predict disease course from SSc diagnosis has been found. Most studies have analysed subgroups of patients who were already at risk for the development of specific organ involvement, such as PAH. 13, 17 Others have investigated predictive factors at one moment in time, without taking into account the follow-up findings. 14 Finally, one study analysed predictive factors from baseline, but also included variables which are time dependent, making the results not clear to be used at the precise time of diagnosis. 15 Therefore, our study has additive value for future research by supplying predictive variables applicable to all SSc patients. All patients diagnosed with SSc, and available clinical baseline data, were included in this cohort. Therefore, our design is also suitable for the calculation of incidence of both pulmonary involvement and death. Furthermore, this cohort is adequate for the development of a prediction model, due to the fairly complete follow-up data. Inclusion of patients from different countries also increases the possibility for a solid analysis of predictive value.
Our study has also some limitations. Patients were lost to follow-up; therefore, the occurrence of organ involvement and death can be underestimated. Due to the retrospective data collection, there is a risk of selection bias since the outcomes have already occurred at the time of selection. The risk of selection bias is estimated to be small because all patients, with and without an occurring event, have been followed in this inception cohort from SSc diagnosis. Despite the large number of patients included in this study, the number of occurring events is small, resulting in only a small number of predictors in the models.
In summary, the predictive properties of several variables already available at the time of SSc diagnosis are shown in this study. Discrimination and calibration of the models showed moderate performance indicating that there are possibilities for prediction of severe organ damage and death at baseline. Further research is necessary to improve the efficacy and success of these models.
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